Danco Laboratories filed an emergency request with the Supreme Court on May 2 asking the justices to immediately block a lower-court order that would force women to visit a doctor in person before obtaining the abortion drug mifepristone, a requirement the Biden administration had eliminated and that the conservative 5th U.S. Circuit Court of Appeals moved to reinstate just one day earlier, as USA TODAY reported.
The filing lands the abortion pill fight back on the Supreme Court's doorstep barely two years after the justices tossed out a similar challenge. This time the plaintiff is not a group of anti-abortion doctors but the state of Louisiana, which argues that mailing mifepristone without an in-person exam lets women sidestep the state's abortion ban and ignores the risk of medical complications.
Mifepristone is used in nearly two-thirds of all abortions across the United States. The stakes could hardly be higher for both sides, and the speed of the legal maneuvering shows it.
On May 1, a three-judge panel of the 5th U.S. Circuit Court of Appeals temporarily reinstated an FDA requirement that doctors prescribe mifepristone only after an in-person examination. The Biden administration had scrapped that safeguard, opening the door to prescriptions by mail and telehealth.
Louisiana challenged the elimination of the in-person requirement, arguing that mail dispensing ignores the threat of complications and enables women to circumvent the state's abortion restrictions. The appeals court agreed, writing that the loosened rule "facilitates nearly 1,000 illegal abortions in Louisiana per month."
That figure alone ought to concentrate minds. If accurate, it means a federal regulatory change, made without congressional action, effectively nullified a state law roughly a thousand times each month in a single state.
Earlier this year, the Trump administration asked a federal judge to pause Louisiana's challenge until the FDA's own safety review of mifepristone is complete. A federal judge agreed. But the 5th Circuit blocked that ruling and ordered the in-person dispensing requirement restored while Louisiana appeals.
The legal back-and-forth between federal courts and executive agencies on this issue has become a familiar pattern. Readers following the broader trend of federal appeals courts setting up Supreme Court showdowns over contested government authority will recognize the dynamic.
In its filing, Danco Laboratories told the Supreme Court that Louisiana's lawsuit suffers from the same defects as the earlier challenge brought by anti-abortion doctors, a case the justices rejected in 2024 on the grounds that those doctors lacked standing.
Danco argued that the 5th Circuit's order "injects immediate confusion and upheaval into highly time-sensitive medical decisions." The company went further:
"Never before has a federal court purported to immediately enjoin a several years' old drug approval; restrict a distribution system for that drug that manufacturers, providers, patients, and pharmacies have all been using for years; or reinstate conditions that FDA determined do not meet the mandatory statutory criteria."
The drugmaker also contended that "Louisiana's complaint should have been dismissed outright." That is a bold claim, and one the justices will now have to weigh against a state government's assertion that its own laws are being circumvented by a federal regulatory change it had no vote on.
This is not the first time the Supreme Court has been asked to intervene in the mifepristone dispute. In 2023, the justices paused a ruling from the same 5th Circuit that would have reimposed the in-person requirement while a lawsuit brought by anti-abortion doctors was still being litigated.
In 2024, the Court rejected that lawsuit entirely, ruling that the doctors lacked a legitimate basis to challenge the FDA's decisions. The question now is whether Louisiana, a sovereign state with its own abortion laws on the books, has the standing the doctors did not.
That distinction matters. A state enforcing its own criminal statutes has a fundamentally different legal posture than a group of physicians claiming indirect harm. Louisiana can point to a concrete, quantifiable impact: the appeals court's own finding of nearly 1,000 illegal abortions per month within its borders, allegedly facilitated by the mail-dispensing rule.
The broader question of how much latitude states retain to enforce their own laws, even when a federal agency has moved in a different direction, echoes through other major legal battles. Texas's long fight to enforce its own migrant arrest law involved a similar tension between state sovereignty and federal preemption.
Complicating the picture further, the Trump administration's FDA is currently reviewing the safety of mifepristone. In January, the administration asked a federal judge to pause Louisiana's legal challenge until that review wraps up. The judge agreed, before the 5th Circuit stepped in.
The Trump administration's position creates an unusual alignment. By asking for a pause rather than siding with Louisiana outright, the administration signaled that it wants the FDA's scientific process to play out before courts impose new restrictions. Whether that posture holds as the case escalates remains to be seen.
Nancy Northup, head of the Center for Reproductive Rights, offered a sharply different read of the FDA review. In a statement, Northup said:
"This isn't about science. It's about making abortion as difficult, expensive, and unreachable as possible."
That framing is predictable from the abortion-rights side. But it sidesteps the core issue Louisiana raised: that a federal rule change is being used to bypass state law. Whether one supports or opposes Louisiana's abortion restrictions, the question of who gets to decide, elected state legislators or unelected federal regulators, is a constitutional one, not merely a medical one.
The justices must now decide, for the second time in three years, whether to intervene in the mifepristone fight. The procedural question is narrow: should the 5th Circuit's reinstatement of the in-person requirement be paused while the legal battle continues? But the substantive implications are enormous.
If the Court blocks the appeals panel's order, mail-order mifepristone continues flowing into states that have banned or restricted abortion. If it lets the order stand, the in-person requirement returns, at least temporarily, and the distribution system that drugmakers, pharmacies, and providers have relied on for years faces disruption.
The high court's handling of emergency applications in politically charged cases has drawn scrutiny from all sides. This case will test whether the justices treat Louisiana's standing argument differently than they treated the doctors' standing argument in 2024. The political dynamics around the court continue to intensify, much as they have in disputes over state-level redistricting battles and executive authority.
Strip away the medical and procedural layers, and the mifepristone case is really about something older and simpler: can a federal agency, by changing a prescribing rule, effectively override a state's criminal law?
Louisiana says no. The Biden-era FDA said, in practice, yes. The Trump administration's FDA is reviewing the matter but has not yet taken a definitive side. And Danco Laboratories, the company that makes the drug, wants the courts to preserve the status quo that has prevailed for years.
For conservatives who believe in federalism and the right of states to set their own policies on matters the Constitution does not expressly reserve to the federal government, Louisiana's argument carries real weight. The state is not asking the Supreme Court to ban mifepristone nationwide. It is asking the Court to let it enforce its own laws without a federal workaround.
Whether the justices see it that way, or whether they again find a procedural off-ramp, as they did in 2024, will shape not just abortion policy but the balance of power between states and federal regulators for years to come. The pattern of state leaders asserting authority against federal overreach is one of the defining features of this political era.
When a federal rule can quietly cancel a state law a thousand times a month, the question is no longer about one pill. It is about who governs.
